Does it matter that organ donors are not dead? Ethical and policy implications

M Potts, D W Evans

The “standard position” on organ donation is that the donor must be dead in order for vital organs to be removed, a position with which we agree. Recently, Robert Truog and Walter Robinson have argued that (1) brain death is not death, and (2) even though “brain dead” patients are not dead, it is morally acceptable to remove vital organs from those patients. We accept and defend their claim that brain death is not death, and we argue against both the US “whole brain” criterion and the UK “brain stem” criterion. Then we answer their arguments in favour of removing vital organs from “brain dead” and other classes of comatose patients. We dispute their claim that the removal of vital organs is morally equivalent to “letting nature take its course”, arguing that, unlike “allowing to die”, it is the removal of vital organs that kills the patient, not his or her disease or injury. Then, we argue that removing vital organs from living patients is immoral and contrary to the nature of medical practice. Finally, we offer practical suggestions for changing public policy on organ transplantation.

In a recent article, Robert Truog and Walter Robinson note: “The practice of organ transplantation has been wedded to the concept of brain death for most of its history”. The link “is the ‘dead donor’ rule, which requires that patients be declared dead before the removal” of unpaired vital organs—for example, heart, liver, or two paired vital organs (such as kidneys). Movement toward changing the criteria of death from cardiopulmonary to brain based criteria was already taking place at Cape Town in 1967, due to pressure for a viable heart for transplantation. The consequence of the recipient’s short survival was, as the BMJ’s deputy editor put it, “a euphoric, uncontrolled epidemic of heart transplantation around the world”. This, together with demand for other organs which required that they be perfused until their removal, necessitated “the production of a set of legal and other organs which required that they be perfused until their last ten years, fresh attacks on brain death criteria have remained the “bible” for diagnosis of death in the US. In the Alan Shewmon, in a newly published anthology, note that eroded their perceived invulnerability. Their conceptual and no discernible central nervous on “irreversible coma” with “death proposed, in 1968, a new set of criteria for death based on irreversible cessation of testable brain function while the body remains alive. One difficulty is the near impossibility of diagnosing— with the necessary certainty—the “irreversible cessation of all functions of the entire brain, including the brain stem” while the rest of the body remains alive. The Harvard tests— essentially of brain stem mediated reflexes and ventilator dependence in patients whose coma appeared irremediable— clearly lacked the power to make that diagnosis. The many protocols now in use worldwide fail similarly. Indeed, their very number proclaims the fact that the syndromes they diagnose cannot be one and the same true entity. And prominent among the variations is the apnoea test, which may lead to the misdiagnosis of respiratory centre failure if inadequately stimulating and, if stringently applied, may itself be the cause of death. Truog and Robinson acknowledge that many patients currently diagnosed “brain dead” do not, in fact, meet the American legal requirements governing that practice. They note that many retain demonstrable brain function—and that this knowledge, which should be a challenge to those certifying death on the basis that there is no such activity—is set aside as not “significant”. That dismissal is similar to the stance assumed by those who supported the brain stem death criteria, whose apnoea appeared permanent. Like the US “whole brain criteria”, the UK criteria—held to define death conceptualised as permanent loss of the capacity for consciousness and the capacity to breathe spontaneously—did not

Abbreviations: EEG, electroencephalogram; UDDA, uniform determination of death act
require the electroencephalogram (EEG) as a test for continuing life in the brain. If recorded, continuing EEG activity was to be disregarded—along with other evidence of persisting brain function—as lacking "significance." It remains unclear, however, on what grounds such activity is disregarded, bearing in mind the present very limited understanding of brain physiology.

Although the term "brain death" is supposed to have gone out of use in the UK,69 comatose, ventilator/dependent patients are still being certified "dead" for transplant purposes using similar tests but on the basis of some idiosyncratic concept that remains far from clear. In the US, criticisms of brain death criteria have remained a matter of academic debate and have not filtered down to the level of public policy. The UDDA and the "dead donor rule" still govern transplantation practice. Truog and Robinson, like others before them,24 25 propose the abandonment of all obfuscation where requests for transplantable organs are concerned. They accept that "brain dead" individuals are alive. The issue then becomes: "Given that brain dead individuals are not dead, is it morally acceptable to remove their organs for transplantation?"

Truog and Robinson answer "yes," and "propose that the ethics of organ donation be based on the ethical principles of non-maleficence and respect for persons rather than on brain death and the dead donor rule". Thus they propose that sometimes the harm of dying is sufficiently small that patients should be allowed to voluntarily accept that harm if it makes organ donation possible. They are not in favour of just anyone donating their vital organs. Rather, they accept the idea that there must be some "threshold" state above which organ donation would not be permitted. It would be permissible to use as donors at least two classes of patients who had given prior consent: the "permanently unconscious" and the "imminently dying". Ultimately, it would be up to "society" to determine the minimal threshold of lively existence below which donation would be permitted. They suggest that organ donation from the "permanently unconscious" be limited to patients declared "brain dead" by current standards, because of uncertainty about the "capacity for consciousness" in patients in a persistent vegetative state or in anencephalic newborns. The "imminently dying" group should initially be limited "to those patients completely dependent on life support, in whom death would be expected within minutes of withdrawal of that support, and in whom no treatment alternatives are available or desired". This would include "patients with cervical quadriplegia who desired withdrawal of mechanical ventilation or patients on cardiac support devices who refused continuation of that support or other treatment alternatives". Such patients would normally grant permission for organ removal themselves, "removing any concerns about the legitimacy of surrogate decision making in cases like this". Practically, these limitations imply that there is "a large gap between the category of patients permitted to have withdrawal of life support and the category of patients permitted to donate organs". The former group will be the larger, because more categories of patients would be allowed to refuse life prolonging treatment than those allowed to donate their organs.

For Truog and Robinson, the case for taking organs from still living donors depends upon "shifting the key ethical question from 'Is the patient dead?' to 'Are the harms of removing life sustaining organs sufficiently small that patients or surrogates should be allowed to consent to donation?'". Their answer to the second question is "yes", at least for some classes of patients. These authors believe that the current practice of harvesting organs from donors "who meet brain death criteria...[is] clearly ethical—not because the patients are dead, but rather because they have been rendered permanently unconscious from an overwhelming brain injury". As far as the larger class of patients eligible for "non-heart beating organ donation" is concerned, a group that includes individuals who do not meet brain death criteria, they suggest that rather than removing their organs after a set period of time following cardiac arrest, it would be better to remove their organs before ischaemic cardiac arrest. This not only overcomes the problem of "orchestrated death in these protocols", it also "optimis[e] both the number and the viability of the organs obtained".

To answer the charge that vital organ removal kills the living patient, Truog and Robinson argue that there is a parallel between organ procurement and ventilator withdrawal: "In both ventilator withdrawal and organ procurement, the physician acts, and this act is the most proximate cause of the patient's death. In both cases, the physician is not morally responsible for the patient's death—the morally relevant cause of death is the patient's disease. In both cases, the physician is acting with the patient's consent in ways that respect the wishes of the patient and that are in the pursuit of morally worthwhile ends."

Once we recognise that the dead donor rule is not morally necessary for organ procurement, the "concept of brain death will then disappear from textbooks, illustrating the degree to which the concept was never more than a social construction, developed to meet the needs of the transplantation enterprise during a crucial phase of its development".

We contend that Truog and Robinson's arguments for the moral acceptability of organ procurement once the dead donor rule is eliminated are unsuccessful, and that the unacceptable-ability of such transplantation should lead to changes in current policy. We believe that removing vital organs from a still living donor is the taking of innocent human life. The argument that such removal is morally no different from "allowing to die" by removing a ventilator is seriously flawed. When a ventilator is removed from an apnoeic comatose patient, it is the disease or injury that causes the loss of the patient's ability to breathe spontaneously. As Margaret Somerville notes: "the withdrawal of life support treatment such as respiratory support involves a situation of multiple causation in which one cause (respiratory failure) is sufficient to cause death; the other cause (turning off the respirator) is not sufficient in the absence of respiratory failure". The situation is different when vital organs are removed from a patient. Removing a vital organ, such as the heart, directly causes the death of the patient, and is not merely allowing the effects of disease or injury to take their course. It is the organ removal surgery that kills the donor. In addition, withdrawal of life support may be an acceptable omission of burdensome treatment, rather than an act that is more likely to involve an intent to kill the patient. The issue in removing vital organs from brain dead individuals is not, therefore, whether to withdraw burdensome life support from a dying patient but whether such organ removal is a morally acceptable form of killing. Truog and Robinson say it is. As Truog says elsewhere, organ transplantation involves "a form of justified killing" since it does not "harm" "those who are permanently and irreversibly unconscious (patients in a persistent vegetative state or newborns with anencephaly) and those who are imminently and irreversibly dying".

Truog and Robinson's proposals that unpaired vital organs be removed from "brain dead" and other classes of patients can be seen as the endorsement of killing people for their organs. One difficulty with this is that once utilitarian considerations are used to justify killing ventilator/dependent patients who are dying, those same considerations could also be used to justify killing non-ventilator/dependent patients or patients who are not dying.

Another major problem with doctors being involved in killing patients is that such a practice by medical professionals fundamentally distorts the nature of medicine itself.
Edmund Pellegrino and David Thomasma have developed the idea that medicine is primarily a relationship between a sick or injured person needing help and the physician or other health care provider who is trained to provide such help. As such, medicine involves morality as part of its very structure, for there is an imbalance of power and knowledge between the health care provider and the patient (whose vulnerability, when ill, exacerbates this imbalance). This implies a responsibility for the health care provider (1) to have the requisite training and skills and to use those skills competently, and (2) to tell the patient the truth, for the patient has the requisite training and skills and to use those to protect the patient by removing his organs is not legitimate even if he (or her) patient in an intimate way. Using such training to kill subverts a ban on the procurement of organs from a donor, the patient’s signing of an organ donor form is not a private decision. Doctors are morally obliged to refuse requests that involve illegitimate exercise of medical power. Requests (oral or written) do not automatically imply an obligation to comply with them. Even if an individual is “brain dead”, killing him for the good of others cannot be justified. Crossing that line is dangerous for patients, who are some of the weakest members of society and dependent upon its protection. If, as we have argued, it is morally wrong to kill patients for their organs, what difference does this make for public policy? If it were generally recognised that “brain dead” patients are alive, would the medical community and general public support a ban on the procurement of organs for transplant from them? Or would they take a position similar to that of Truog and Robinson, holding that even if organ donors are alive, the loss of their lives does such little harm that removing their organs is morally acceptable? There might, perhaps, be support from some for the Truog and Robinson proposal to extend the pool of organ donors beyond those who are “brain dead”. Others, however, might be deeply disturbed that living patients are being used as organ donors and would refuse to sign organ donor cards. A key point is that individuals are not able to understand the issues, and therefore cannot give informed consent to organ donation, if they do not receive accurate information about the procedure. They should know that, in current practice, most organs for transplant are taken from “brain dead” individuals who are not dead in the sense that their circulation and respiration have ceased, or that their brains are really and truly dead. They should be aware that the diagnosis of “brain death” is not soundly based or universally accepted, and that there are serious questions about its constituting the death of the person. The public should also be aware that there remains uncertainty regarding the generation of consciousness in the brain, and that it is not always clear that there is no capacity for consciousness remaining in individuals declared “brain dead”. Much of the information given to the public regarding organ donation and the declaration of death comes through literature in support of people signing organ donor cards. Currently, the statement on organ donor cards asserts that organs may be taken “after my death”. We believe that such wording should be changed to reflect the fact that “brain dead” individuals are not dead in the usual understanding of what death is. Explanatory literature accompanying organ donor cards should be frank that a “brain dead” donor’s heart is beating during part of the organ removal surgery. There should be open public discussion and debate on the determination of death instead of the current domination of the orthodox “whole brain death” (US) or “brain stem death” (UK) positions. Pluralism on the issue of the determination of death should be publicly acknowledged. Proposals to make organ donation the “default” unless the potential donor says otherwise should be rejected, since such policies are not only open to abuse, but also too easily allow patients who oppose brain death criteria to become organ donors against their wishes. Another difficulty is that such “presumed consent” cannot be valid unless all those eligible to be donors under these policies—that is, the public as a whole—fully understand the organ procurement procedures.

We welcome Truog and Robinson’s admission that “brain dead” individuals are not dead and that brain death criteria were developed to allow vital organ donation, rather than being on a firm scientific or philosophical basis. We sharply disagree, however, with their position that it is morally acceptable for this to continue, albeit on some new understanding of what is being done. The general acceptance of the practice since 1968 (in the US) is irrelevant to its moral rightness or wrongness.

REFERENCES

The use of generic or patent medicines in the Netherlands

In September 1998 the Dutch Ministry of Health together with the Dutch Society of General Practitioners (LHV), the Royal Dutch Society of Pharmacists (KNMP), and the Dutch Patient and Consumer Federation (NPCF) published a pamphlet entitled: *The same medicine in a different coat. Drugs without a trademark, equally effective, but cheaper*. Patients could obtain a copy at the local pharmacy or pratice by paying the cost of the general practitioner. It deals with the question whether the name of the patent drug should be written on the prescription or only the active (generic) component. This is important because, according to the authors, the costs of health care can be reduced without reducing the quality of the care if the doctor prescribes the generic form. It is also mentioned that another advantage of prescribing the generic form is that, contrary to the patent drug, it is known under the same name in all countries. This enables pharmacists and doctors everywhere to establish directly which drug the patient is using. As a precaution it is also stated that, in some special cases, it remains necessary to administer the patent drug, for instance, if the right dose is not availible in the generic form.

On 19 July 2003 there appeared in the national newspaper, *Trouw*, an advertisement which contained a very different message. This time an association of leading pharmaceutical companies in the Netherlands, Nefarma, had replaced the Ministry of Health and the pharmacists (KNMP) as coauthors. In large print the readers were informed as follows: “Save money? Not at the expense of your health. Do not accept another medicine, another composition or dose. The government wants to save money, for instance, on the costs of drugs. Of course this should never be at the expense of your health. Especially for the elderly and the chronically ill patients, who regularly need medicines, such a policy would have great consequences. Also the health insurance companies are involved and are of the opinion that the lower the costs of medicines, the better. It is quite likely that in this tumult you, as a patient, can no longer determine what should be done. Without the doctor’s and your permission the pharmacist may not dispense from the medicine, written on the prescription”. The advertisement includes a number of drawings: in one of these the doctor gives the patient a prescription for drug A and in another the pharmacist has exchanged this for drug B, which the patient refuses to accept.

I believe that such an advertisement is unethical. The patient is made afraid that his treatment is interfered with in a detrimental way by the pharmacist. Recently de Visser, the manager of Nefarma, published an article in a Dutch medical journal in which he clarified his opinion on this matter. De Visser makes it clear that it is illegal for pharmacists to deliver to the patient a generic drug if the doctor has written on the prescription a different (patent) medicine. He also stresses that only the physician knows the disease from which the patient suffers and that he is therefore the only one who can determine which medicine the patient needs. In this article the director of the Dutch Society of General Practitioners, H van Baasbank, reports that the society has: “received signals that without approval of their GP, patients have received from pharmacists an undesirable replacement of patent drugs by generic drugs”. A member of the board of the Royal Dutch Society of Pharmacists (KNMP) presents his case in the same paper. He affirms that the pharmacist knows the regulations on what to do when there is a conflict between generic and patent medicines. His motives are based on the price of the drug as long as the effect is the same. He reproaches Nefarma for creating this animosity between the parties solely because it fears loss of profit if more generic drugs are prescribed. It is clear that patients, who are, in general, not aware of the background of this power struggle, are bewildered. In my opinion the advertisement should never have appeared in the newspaper. The sooner the conflict is resolved by discussion between the parties, the better it will be for all concerned.

D O E Gebhardt
Anna van Burenlaan 1, 2341 VE Oegstgeest, Netherlands; doe.gebhardt@planet.nl

REFERENCES

1 De Visser C. An opinionated attitude is not proper for the pharmacist. *Med Contact* 2003;58:1227–9.

LETTER

The use of generic or patent medicines in the Netherlands

I believe that such an advertisement is unethical. The patient is made afraid that his treatment is interfered with in a detrimental way by the pharmacist. Recently de Visser, the manager of Nefarma, published an article in a Dutch medical journal in which he clarified his opinion on this matter. De Visser makes it clear that it is illegal for pharmacists to deliver to the patient a generic drug if the doctor has written on the prescription a different (patent) medicine. He also stresses that only the physician knows the disease from which the patient suffers and that he is therefore the only one who can determine which medicine the patient needs. In this article the director of the Dutch Society of General Practitioners, H van Baasbank, reports that the society has: “received signals that without approval of their GP, patients have received from pharmacists an undesirable replacement of patent drugs by generic drugs”. A member of the board of the Royal Dutch Society of Pharmacists (KNMP) presents his case in the same paper. He affirms that the pharmacist knows the regulations on what to do when there is a conflict between generic and patent medicines. His motives are based on the price of the drug as long as the effect is the same. He reproaches Nefarma for creating this animosity between the parties solely because it fears loss of profit if more generic drugs are prescribed. It is clear that patients, who are, in general, not aware of the background of this power struggle, are bewildered. In my opinion the advertisement should never have appeared in the newspaper. The sooner the conflict is resolved by discussion between the parties, the better it will be for all concerned.

D O E Gebhardt
Anna van Burenlaan 1, 2341 VE Oegstgeest, Netherlands; doe.gebhardt@planet.nl

REFERENCES

1 De Visser C. An opinionated attitude is not proper for the pharmacist. *Med Contact* 2003;58:1227–9.